Table 1.

Specific α7nAChR pharmaceutical agonists investigated in the literature for their in vivo therapeutic effects on the pathogenesis of a number of inflammatory conditions

α7nAChR specific agonist	Animal model	Inflammatory condition	Outcome	Reference
GTS-21	Mouse	Endotoxemia/  sepsis	Improved survival coinciding with decreased serum levels of TNF-α and HMGB1	[66]
	Mouse	Pancreatitis	Lower pancreatic inflammation with decreased plasma levels of IL-6 and amylase	[67]
PNU-282987	Mouse	Acute lung injury	Decreased excess lung water and lung vascular permeability with reduced TNF-α and MIP2 in BAL	[68]
AR-R17779	Mouse	Rheumatoid  arthritis	Ameliorated clinical arthritis and reduced synovial inflammation with a reduction of TNF-α levels	[33]
	Mouse	Intestinal  inflammation	Prevents postoperative ileus characterised by reduced inflammatory cell recruitment	[69]
DMPP	Mouse	Asthma	Reduced airway inflammation with reduced IgE and number of eosinophils in BAL	[70]
TC-7020	Mouse	Type 2 diabetes	Reduced weight gain, glucose and glycated hemoglobin levels and lowered plasma levels of TNF-α	[71]